Among the presentations at the European Society for Medical Oncology meeting in Barcelona, Spain will be data for older immune checkpoint inhibitors from Merck & Co., Inc., AstraZeneca PLC and Bristol Myers Squibb Company in earlier lines of treatment, plus new results from the troubled TIGIT class. An array of early-stage results for innovative anticancers including drugs targeting claudin-6 and CDK2, and protein degraders will also be on show, at the conference which will run from 13-17 September.
What To Look Out For At ESMO 2024
Attendees at this year's European Society for Medical Oncology meeting in Barcelona can look forward to a range of interesting datasets, from Phase III trials of established products in new settings to preliminary studies of novel products coming through the pipeline.
